

1614 \$



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: José Zayas-Rivera)	Group Art Unit: 1614
)	
Application No.: 10/016,726)	Examiner: Kevin E. Weddington
)	
Filed: October 30, 2001)	
)	
For: MEDICAL APPLICATION OF)	INFORMATION DISCLOSURE
OXIDIZED MONOTERPENES)	STATEMENT UNDER 37 C.F.R. §
)	1.97(c)(2)
)	
)	

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97(c)(2), applicant brings to the attention of the Examiner the documents listed on the attached form. The fee set forth in 37 C.F.R. §1.17(p) is included.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants

04/21/2004 HALI11 00000026 10016726

01 FC:1806

180.00 OP

ALPHA-0200

reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 501,452.

Respectfully submitted,

April 14, 2004

By: 

Heath W. Hoglund
Registration No. 41,076
256 Eleanor Roosevelt
San Juan, PR 00918
Tel.: 787-772-9200
Fax: 787-772-9533



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: José Zayas-Rivera)	Group Art Unit: 1614
)	
Application No.: 10/016,726)	Examiner: Kevin E. Weddington
)	
Filed: October 30, 2001)	
)	CERTIFICATE OF MAILING
For: MEDICAL APPLICATION OF)	
OXIDIZED MONOTERPENES)	
)	
)	

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence including:

- Information Disclosure Statement by Applicant
- Information Disclosure Statement under 37 C.F.R. § 1.97(b)
- Credit Card Payment Form

is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to:


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

April 14, 2004

By: 

Heath W. Hoglund
Registration No. 41,076
256 Eleanor Roosevelt
San Juan, PR 00918
Tel.: (787) 772-9200
Fax: (787) 772-9533

ALPHA-0200



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if known

Application Number	10/016,726
Filing Date	10/30/01
First Named Inventor	Zayas
Group Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	ALPHA-0200

Sheet 1 of 2

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	U. S. Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
		Number		MM-DD-YYYY
	AA	5,294,645	Chastain, <i>et al.</i>	03-15-1994
	AB	5,411,992	Eini, <i>et al.</i>	05-02-1995
	AC	5,763,415	Sukumar	06-09-1998
	AD			
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AL			
	AM			
	AN			
	AO			
	AP			
	AQ			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Documents MM- DD-YYYY
		Country	Number		
	BA				
	BB				
	BC				
	BD				
	BE				
	BF				
	BG				
	BH				
	BI				
	BJ				

Examiner
Initials

Date
Considered

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***Complete if Known*

Application Number	10/016,726
Filing Date	10/30/01
First Named Inventor	Zayas
Group Art Unit	1614
Examiner Name	Kevin E. Weddington
Attorney Docket Number	ALPHA-0200

Sheet

2

of

2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTER), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page (s), volume-issue number(s), publisher, city and/or country where published.
	CA	PAMELA L. CROWELL, REBEKAH R. CHANG, ZHIBIN REN, CHARLES E. ELSON, and MICHAEL N. GOULD; <i>Selective Inhibition of Isoprenylation of 21-26-kDa Proteins by the Anticarcinogen d-Limonene and its Metabolites</i> ; <u>The Journal of Biological Chemistry</u> ; 1991; Vol. 266, No. 26, pp. 17679, 17681-17685; USA
	CB	JILL D. HAAG, MARY J. LINDSTROM, AND MICHAEL N. GOULD; <i>Limonene-induced Regression of Mammary Carcinomas</i> ; <u>Cancer Research</u> ; 1992; pp. 4021-4026; USA
	CC	BANDARU S. REDDY, C-X. WANG, HANAN SAMAHA, RONALD LUBET, VERNON E. STEELE, GARY J. KELLOFF, and CHINTHALAPALLY V. RAE; <i>Chemoprevention of Colon Carcinogenesis by Dietary Perillyl Alcohol</i> ; <u>Cancer Research</u> ; 1997; pp. 420-425; USA
	CD	GREGORY H. RIPPLE, MICHAEL N. GOULD, JAMES A. STEWART, KENDRA D. TUTSCH, RHODA Z. ARZOOMANIAN, DONA ALBERTI, CHRIS FEIERABEND, MARCIA POMPLUN, GEORGE WILDING, and HOWARD H. BAILEY; <i>Phase I Clinical Trial of Perillyl Alcohol Administered Daily</i> ; <u>Clinical Cancer Research</u> ; 1998; pp 1159-1164; USA
	CE	MARGARET BARTHELMAN, WEIXING CHEN, HELEN L. GENSLER, CHUANSHU HUANG, ZIGANG DONG, and G. TIM BOWDEN; <i>Inhibitory Effects of Perillyl Alcohol on UVB-induced Murine Skin Cancer and AP-1 Transactivation</i> ; <u>Cancer Research</u> ; 1998; pp. 711-716; USA
	CF	PIET J. M. BOON, DENNIS VAN DER BOON, and GERARD J. MULDER; <i>Cytotoxicity and Biotransformation of the Anticancer Drug Perillyl Alcohol in PC12 Cells and in the Rat</i> ; <u>Toxicology and Applied Pharmacology</u> ; 2000; pp. 55-61; USA
	CG	GREGORY H. RIPPLE, MICHAEL N. GOULD, RHODA Z. ARZOOMANIAN, DONA ALBERTI, CHRIS FEIERABEND, KRIS SIMON, KIM BINGER, KENDRA D. TUTSCH, MARCIA POMPLUN, ANY WAHAMAKI, REBECCA, MARNOCHA, GEORGE WILDING, and HOWARD H. BAILEY; <i>Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day</i> ; <u>Clinical Cancer Research</u> ; 2000; pp. 390-396; USA
	CH	GARY R. HUDES, CHRISTINE E. SZARKA, ANDREA ADAMS, SULABHA RANGANATHAN, ROBERT A. McCAULEY, LOUIS M. WEINER, COREY J. LANGER, SAMUEL LITWIN, GWEN YESLOW, THERESA HALBERR, MINGXIN QIAN, and JAMES M. GALLO; <i>Phase I Pharmacokinetic Trial of Perillyl Alcohol (NSC 641066 in Patients with Refractory Solid Malignancies</i> ; <u>Clinical Cancer Research</u> ; 2000; pp. 3071-3080; USA

Examiner
SignatureDate
Considered